본문 바로가기
KERD
논문KCI 등재

Optimizing the Dose and Duration of Therapy for Chronic Hepatitis C

Nipaporn Pichetshote|Erik Groessl|Helen Yee|Samuel B. Ho
거트앤리버 소화기연관학회협의회|2009.03|Gut and Liver|제3권 제1호|pp. 1-13

2

조회

0

다운로드

0

인용

0

참고문헌

초록

Recent studies indicate that antiviral treatment with pegylated interferon alfa and ribavirin for hepatitis C can be individualized based on viral and host characteristics and the pattern of virologic response during the initial months of antiviral treatment. Patients with a low initial viral load who demonstrate a rapid virologic response to antiviral therapy may be treated with a shorter duration of therapy and are less sensitive to reduced dosing of ribavirin. Patients with delayed virologic response will require a longer duration of therapy - up to 72 weeks for patients with genotype 1 - in order to optimize chances of a sustained virologic response. Patients who were nonresponders or relapsed after an acceptable course of antiviral therapy may be retreated using a more intensive regimen and/or a longer duration of therapy. Previous nonresponders to pegylated interferon alfa and ribavirin are less likely to respond to retreatment unless they demonstrate a virologic response within the first three months of retreatment, lack advanced fibrosis, and can tolerate a more intensive and/or lengthier treatment. Individualized treatment based on viral genotype, viral load, the presence of advanced fibrosis, and initial virologic response can improve therapy for some patients and save resources in others.

Abstract

Recent studies indicate that antiviral treatment with pegylated interferon alfa and ribavirin for hepatitis C can be individualized based on viral and host characteristics and the pattern of virologic response during the initial months of antiviral treatment. Patients with a low initial viral load who demonstrate a rapid virologic response to antiviral therapy may be treated with a shorter duration of therapy and are less sensitive to reduced dosing of ribavirin. Patients with delayed virologic response will require a longer duration of therapy - up to 72 weeks for patients with genotype 1 - in order to optimize chances of a sustained virologic response. Patients who were nonresponders or relapsed after an acceptable course of antiviral therapy may be retreated using a more intensive regimen and/or a longer duration of therapy. Previous nonresponders to pegylated interferon alfa and ribavirin are less likely to respond to retreatment unless they demonstrate a virologic response within the first three months of retreatment, lack advanced fibrosis, and can tolerate a more intensive and/or lengthier treatment. Individualized treatment based on viral genotype, viral load, the presence of advanced fibrosis, and initial virologic response can improve therapy for some patients and save resources in others.

참고문헌 (57)

  1. Dienstag JL, "American Gastroenterological Association technical review on the management of hepatitis C", Gastroenterology 2006;130:231-264., 130, pp.231~264 (2006)
  2. Armstrong GL, "The prevalence of hepatitis C virus infection in the United States, 1999 through 2002", Ann Intern Med, 144, pp.705~714 (2002)
  3. Edlin BR, "Five million Americans infected with the hepatitis C virus: a corrected estimate", Hepatology, 42, pp.213A~ (2005)
  4. Davis GL, "Projecting future complications of chronic hepatitis C in the United States", Liver Transpl, 9, pp.331~338 (2003)
  5. Wong JB, "Estimating future hepatitis C morbidity, mortality, and costs in the United States", Am J Public Health, 90, pp.1562~1569 (2000)
  6. Rodger AJ, "The impact of diagnosis of hepatitis C virus on quality of life", Hepatology, 30, pp.1299~1301 (1999)
  7. Foster GR, "Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis", Hepatology, 27, pp.209~212 (1998)
  8. Gifford SM, "Australian women's experiences of living with hepatitis C virus: results from a cross-sectional survey", J Gastroenterol Hepatol, 18, pp.841~850 (2003)
  9. Groessl EJ, "Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans", J Gen Intern Med, 23, pp.1959~1965 (2008)
  10. McHutchison JG, "Chronic hepatitis C: an age wave of disease burden", Am J Manag Care, 11, pp.S286~S295 (2005)
  11. Bruno S, "Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study", Hepatology, 45, pp.579~587 (2007)
  12. Veldt BJ, "Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis", Ann Intern Med, 147, pp.677~684 (2007)
  13. Mallet V, "Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C", Ann Intern Med, 149, pp.399~403 (2008)
  14. Dienstag JL, "American Gastroenterological Association medical position statement on the management of hepatitis C", Gastroenterology, 130, pp.225~230 (2006)
  15. Muir AJ, "Peginterferon alfa- 2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites", N Engl J Med, 350, pp.2265~2271 (2004)
  16. Blonsky JJ, "Review article: nonalcoholic fatty liver disease and hepatitis C virus--partners in crime", Aliment Pharmacol Ther, 27, pp.855~865 (2008)
  17. Yee HS, "Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office", Am J Gastroenterol, 101, pp.2360~2378 (2006)
  18. Ferenci P, "Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)", ribavirin, 2005, pp.43, 425~433
  19. Mangia A, "Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial", Hepatology, 47, pp.43~50 (2008)
  20. Pearlman BL, "Chronic hepatitis C therapy: changing the rules of duration", Clin Gastroenterol Hepatol, 4, pp.963~971 (2006)
  21. Pearlman BL, "Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it", World J Gastroenterol, 14, pp.3621~3627 (2008)
  22. Leevy CB, "Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin", Dig Dis Sci, 53, pp.1961~1966 (2008)
  23. Ferenci P, "Peginterferon alfa- 2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response", Gastroenterology, 135, pp.451~458 (2008)
  24. Reau N, "Evaluation of early null-response as a predictor of nonresponse to PEG RBV in patients with HCV", Hepatology, 48, pp.863A~864A (2008)
  25. Sulkowski MS, "Probability of sustained virologic response is associated with the magnitude of HCV RNA reduction at week 4 of treatment with peginterferon plus ribavirin: results of the IDEAL trial", Hepatology, 48, pp.1144A~ (2008)
  26. Shiffman ML, "Peginterferon alfa- 2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3", N Engl J Med, 357, pp.124~134 (2007)
  27. Davis GL, "Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C", Hepatology, 38, pp.645~652 (2003)
  28. Jensen DM, "Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)", ribavirin therapy, 2006, pp.43, 954~960
  29. Hadziyannis SJ, "Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
  30. Zeuzem S, "Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia", J Hepatol, 44, pp.97~103 (2006)
  31. Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa- 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
  32. Berg T, "Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin", Gastroenterology, 130, pp.1086~1097 (2006)
  33. Pearlman BL, "Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders", Hepatology, 46, pp.1688~1694 (2007)
  34. Ferenci P, "Response-guided therapy with peginterferon alfa-2a (40Kd) plus ribavirin in patients with chronic hepatitis C genotype 1 or 4: Prospective randomized study of extended therapy in patients without a rapid virological response", Hepatology, 48, pp.357A~ (2008)
  35. Bronowicki JP, "Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin", Gastroenterology, 131, pp.1040~1048 (2006)
  36. McHutchison JG, "Adherence to combination therapy enhances sustained response in genotype- 1-infected patients with chronic hepatitis C", Gastroenterology, 123, pp.1061~1069 (2002)
  37. Reddy KR, "Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a", ribavirin treatment, 2007, pp.5, 124~129
  38. Andriulli A, "Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin", J Viral Hepat, 16, pp.28~35 (2009)
  39. Shiffman ML, "Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C", Gastroenterology, 132, pp.103~112 (2007)
  40. Teuber G, "Retreatment with pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin", Gastroenterology, 124, pp.A768~ (2003)
  41. Sulkowski MS, "PEG-interferon alfa-2b + ribavirin for treatment of patients with chronic hepatitis C who have previouosly failed to achieve a sustained virologic response following interferon alfa or interferon alfa-2b + ribavirin therapy", Gastroenterology, 124, pp.A783~ (2003)
  42. Lawitz EJ, "Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy", Gastroenterology, 124, pp.A783~ (2003)
  43. Jacobson IM, "A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C", Am J Gastroenterol, 100, pp.2453~2462 (2005)
  44. Gross J, "Double-dose peginterferon alfa-2b with weight-based ribavirin improves response for interferon", ribavirin non-responders with hepatitis C: final results of "Renew", 2005, pp.24, 219A~220A
  45. Shiffman ML, "Chronic hepatitis C: treatment of pegylated interferon", ribavirin nonresponders, 2006, pp.8, 46~52
  46. Poynard T, "Sustained Viral Responses (SVR) is dependent on baseline characteristics in the retreatment of previous Alfa Interferon", Ribavirin (I, J Hepatol, pp.2008, 48[DOI]
  47. Jensen DM, "Pegylated interferon alfa-2a (40kd) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12kd)", RBV: Final efficacy and safety outcomes of the REPEAT study, 2007, pp.46, 291A~
  48. Kaiser S, "Successful retreatment of interferon", ribavirin nonresponders with daily dosing of consensus interferon, 2005, pp.42, S207~208
  49. Bacon B, "The Direct Trial (daily-dose consensus interferon and ribavirin: efficacy of combined therapy): Treatment of nonresponders to previous pegylated interferon plus ribavirin: Sustained virologic response data", Hepatology, 46, pp.311A~ (2007)
  50. Sánchez-Tapias JM, "Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment", Gastroenterology, 131, pp.451~460 (2006)
  51. Dalgard O, "Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study", Hepatology, 40, pp.1260~1265 (2004)
  52. Mangia A, "Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3", N Engl J Med, 352, pp.2609~2617 (2005)
  53. von Wagner M, "Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C", Gastroenterology, 129, pp.522~527 (2005)
  54. Dalgard O, "Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response", Hepatology, 47, pp.35~42 (2008)
  55. Lagging M, "Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2", 3 infection, 2008, pp.47, 1837~1845
  56. Willems B, "Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2", 3 without a rapid virological response?, 2007, pp.46, S6~
  57. Shiffman ML, "Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment", Gastroenterology, 126, pp.1015~1023 (2004)

관련 논문AI추천

Chronic Hepatitis C장재영, Raymond T. Chung거트앤리버 소화기연관학회협의회 · Gut and Liver2011 · 제5권 제2호Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis권영오, 김경훈, 서정일, 이창형, 이헌주, 장병국, 정우진, 탁원영, 황재석대한간학회 · Clinical and Molecular Hepatology2011 · 제17권 제3호Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea고광철, 곽금연, 백승운, 백용한, 유병철, 이준혁, 조현진, 최문석거트앤리버 소화기연관학회협의회 · Gut and Liver2013 · 제7권 제5호Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin김종한, 김지현, 박성재, 설상영, 송영진, 이상헌, 이연재, 이재익, 정은욱, 지삼룡, 최병진, 최상분, 최정식대한간학회 · Clinical and Molecular Hepatology2011 · 제17권 제3호Durability of Sustained Virologic Response in Chronic Hepatitis CAhmet Danalioglu, Ahmet Uyanikoglu, Binnur Pinarbasi, Fatih Besisik, Fatih Ermis, Filiz Akyuz, Kadir Demir, Sabahattin Kaymakoglu, Yilmaz Cakaloglu거트앤리버 소화기연관학회협의회 · Gut and Liver2013 · 제7권 제4호Hepatitis C Viral Kinetics as a Determinant of Stopping Pegylated Interferon and Ribavirin in Genotype 1 Infection김도영거트앤리버 소화기연관학회협의회 · Gut and Liver2014 · 제8권 제4호

이 간행물의 다른 논문 (11건)

Immune Activation and Gut Microbes in Irritable Bowel SyndromeHenry C. Lin, Khaldun Al-Khatibpp. 14-19Recombinant Interferon-Beta-1α Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot StudyYong Soo Kim, Ja Kyung Kim, Chae Yoon Chon, Young Myoung Moon, Hyun Woong Lee, 안상훈, Kwang-Hyub Hanpp. 20-25Plasma 5-Hydroxytryptamine Concentration and Its Correlation with Psychopathology in Patients with Irritable Bowel Syndrome김현수, 유종선, 최성규, 조성범, Chang-Hwan Park, 이완식, Seon-Young Park, Kyoung-Won Yoon, Min-Ho Parkpp. 26-30Treatment of Gastric Candidiasis in Patients with Gastric Ulcer Disease: Are Antifungal Agents Necessary?탁원영, 정민규, 김성국, 최용환, 전성우, 권영오, 조창민pp. 31-34Colorectal Neoplasm in Asymptomatic Average-risk Koreans: The KASID Prospective Multicenter Colonoscopy Survey진윤태, 최황, Suk-Kyun Yang, 변정식, Jai Hyun Choi, Hye-Won Park, Moon Sung Lee, Il-Kwon Chung, Jae Suk Song, 김현수, 박동일, 정성애, 김태일, 김원호, 한동수, 김효종, Young-Ho Kim, 최규용pp. 35-40
원문 보기